China Accepts Opamtistomig NDA with Priority Review in Rare Neuroendocrine Carcinoma
China’s Center for Drug Evaluation (CDE) has accepted Nanjing Leads Biolabs’ New Drug Application for opamtistomig (LBL-024), a PD-L1 x 4-1BB bispecific antibody, and granted it Priority Review for extrapulmonary neuroendocrine carcinoma (EP-NEC), an…
